If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Medical Affairs » Medical Science Liaison
Download FREE Excerpt
14 Info Graphics
16 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
As payers and regulatory bodies increasingly demand real world evidence for key decision making, it is important to reflect key stakeholder perspectives in Phase IV study design and execution. And MSLs are well positioned to be a conduit of HCP, thought leader, and payer insights about the evidence generation targets that matter most.
However, optimizing MSL contributions requires that organizations allocate the right field medical personnel at the right times in the Phase IV development and execution process.
Best Practices, LLC undertook this benchmarking research to probe how leading pharmaceutical and biotech organizations are raising Phase IV performance and value through optimal involvement of MSLs. This study characterizes the MSL contributions most essential to Phase IV, spotlights Phase IV opportunity fronts for MSL deployment, along with the field team skills and training that help maximize MSL impact on Phase IV studies.
Best Practices, LLC engaged 43 Medical Affairs leaders from 31 pharmaceutical and biotechnology companies in this research through a benchmarking survey and interviews.
If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.